Pharma Pulse 12/12/24: Coverage from Trade & Channel Strategies 2024, ASHP Midyear & more

Trade & Channel Strategies 2024: Access and Channel 2024 Year-in-Review and Preview of 2025

This year’s Trade & Channel Strategies Conference in Philadelphia kicked off with a keynote address from Bill Roth, SVP of IntegriChain’s consulting business, Blue Fin Group, and Pharma Commerce board member. Titled “Access and Channel 2024 Year-in-Review and Preview of 2025”, Roth discussed the current reimbursement landscape, how the evolving site-of-care trends are shaping patient access and channel dynamics, and the influence of cost of goods on channel strategies and profitability.

ASHP Midyear: High Costs of Gene Therapies Present Major Challenges to Implementation

According to the report, 75% of survey participants expect pharmacists to oversee these therapies and 58% expect Medicare will require pharmacist involvement.

Lawmakers Eye Bill Forcing Drug Middlemen to Sell Pharmacies

A bipartisan coalition of US lawmakers has drafted legislation that would force prescription drug middlemen to divest pharmacies they own.

New Data From SonarMD Finds that Anxiety Increases Risks for Inflammatory Bowel Disease Flares and Disease Severity

SonarMD presented new clinical findings describing the association between anxiety and increased risk for flares and higher disease severity in inflammatory bowel disease (IBD), emphasizing the importance of integrating mental health support within VBC models for IBD management. This poster was shared at the Advances in Inflammatory Bowel Diseases (AIBD) conference in Orlando, FL (Dec. 9-11, 2024).

AllazoHealth on LinkedIn

At the most foundational level, we want to use identified patient data. When we do so, we can actually then make accurate predictions about nonadherence. Tune in to find out how.

Have news you want us to share in Pharma Pulse? Reach out to Social Media Editor Miranda Schmalfuhs